These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 27450507)

  • 21. Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy.
    Lauffenburger JC; Rhoney DH; Farley JF; Gehi AK; Fang G
    Pharmacotherapy; 2015 Jun; 35(6):560-8. PubMed ID: 26044889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
    Brunetti L; Chen C; White J
    Consult Pharm; 2014 Mar; 29(3):169-78. PubMed ID: 24589766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
    Waks JW; Zimetbaum PJ
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study.
    Wang SV; Franklin JM; Glynn RJ; Schneeweiss S; Eddings W; Gagne JJ
    BMJ; 2016 May; 353():i2607. PubMed ID: 27221664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
    Eikelboom JW; Connolly SJ; Hart RG; Wallentin L; Reilly P; Oldgren J; Yang S; Yusuf S
    J Am Coll Cardiol; 2013 Sep; 62(10):900-8. PubMed ID: 23770182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
    Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
    Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study.
    Staerk L; Gislason GH; Lip GY; Fosbøl EL; Hansen ML; Lamberts M; Bonde AN; Torp-Pedersen C; Olesen JB
    Europace; 2015 Aug; 17(8):1215-22. PubMed ID: 25995392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
    Larsen TB; Rasmussen LH; Skjøth F; Due KM; Callréus T; Rosenzweig M; Lip GY
    J Am Coll Cardiol; 2013 Jun; 61(22):2264-73. PubMed ID: 23562920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study.
    Gorst-Rasmussen A; Skjøth F; Larsen TB; Rasmussen LH; Lip GY; Lane DA
    J Thromb Haemost; 2015 Apr; 13(4):495-504. PubMed ID: 25594442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different risk factors for bleeding and discontinuation between dabigatran and rivaroxaban.
    Nishino M; Okamoto N; Tanaka A; Mori N; Hara M; Yano M; Makino N; Egami Y; Shutta R; Tanouchi J
    J Cardiol; 2016 Aug; 68(2):156-60. PubMed ID: 26443373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Bleeding Events Requiring Hospitalization in Patients With Atrial Fibrillation Receiving Dabigatran, Warfarin, or Antiplatelet Therapy.
    Riley TR; Gauthier-Lewis ML; Sanchez CK; Riley TT
    J Pharm Pract; 2017 Apr; 30(2):214-218. PubMed ID: 26951615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
    Larsen TB; Gorst-Rasmussen A; Rasmussen LH; Skjøth F; Rosenzweig M; Lip GY
    Am J Med; 2014 Jul; 127(7):650-656.e5. PubMed ID: 24530792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
    Larsen TB; Rasmussen LH; Gorst-Rasmussen A; Skjøth F; Lane DA; Lip GY
    Am J Med; 2014 Dec; 127(12):1172-8.e5. PubMed ID: 25193361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dabigatran for the prevention and treatment of thromboembolic disorders.
    Enriquez A; Baranchuk A; Redfearn D; Simpson C; Abdollah H; Michael K
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):529-40. PubMed ID: 25843430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the predictive performance of bleeding risk scores in patients with non-valvular atrial fibrillation on oral anticoagulants.
    Beshir SA; Aziz Z; Yap LB; Chee KH; Lo YL
    J Clin Pharm Ther; 2018 Apr; 43(2):209-219. PubMed ID: 29030869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
    Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
    J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
    Flaker G; Lopes RD; Al-Khatib SM; Hermosillo AG; Hohnloser SH; Tinga B; Zhu J; Mohan P; Garcia D; Bartunek J; Vinereanu D; Husted S; Harjola VP; Rosenqvist M; Alexander JH; Granger CB;
    J Am Coll Cardiol; 2014 Mar; 63(11):1082-7. PubMed ID: 24211508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of dabigatran and warfarin for stroke prevention in elderly Asian population with nonvalvular atrial fibrillation: An audit of current practice in Malaysia.
    Yap SH; Ng YP; Roslan A; Kolanthaivelu J; Koh KW; P'ng HS; Boo YL; Hoo FK; Yap LB
    Med J Malaysia; 2017 Dec; 72(6):360-364. PubMed ID: 29308774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors driving the use of warfarin and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
    Hu MM; Wang J; Chien KL; Su CL; Lin SY; Wu FL; Lin ZF
    J Formos Med Assoc; 2017 Apr; 116(4):276-286. PubMed ID: 27424804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?
    Go AS; Hylek EM; Chang Y; Phillips KA; Henault LE; Capra AM; Jensvold NG; Selby JV; Singer DE
    JAMA; 2003 Nov; 290(20):2685-92. PubMed ID: 14645310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.